Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3602.68% is 71% above its 3-year average of -12475.22%, near the high end of its 3-year range (-1611600.00%–0.00%).
7.22% below its 12-month average of -3360.04%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -6832.84%.
NET PROFIT MARGIN
-3602.68%
NET PROFIT MARGIN AVG TTM
-3360.04%
NET PROFIT MARGIN AVG 3Y
-14337.31%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-7.22%
CURRENT VS 3Y AVG
+74.87%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.00%
median of 789 covered companies
CURRENT VS SECTOR MEDIAN
N/A
vs the sector median at left
CG Oncology Inc.
Market Cap
$5.66B
Net Profit Margin
-3602.68%
TTM Avg
-3360.04%
3Y Avg
-14337.31%
5Y Avg
N/A
Market Cap
$5.76B
Net Profit Margin
9.59%
TTM Avg
-0.75%
3Y Avg
21.75%
5Y Avg
-53.79%
Market Cap
$5.52B
Net Profit Margin
-10.21%
TTM Avg
-9.94%
3Y Avg
-7.18%
5Y Avg
-7.18%
Market Cap
$5.82B
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$5.91B
Net Profit Margin
-89.09%
TTM Avg
-187.61%
3Y Avg
-9430.16%
5Y Avg
-6286.77%
Market Cap
$5.95B
Net Profit Margin
67.88%
TTM Avg
22.01%
3Y Avg
16.68%
5Y Avg
14.76%
Market Cap
$5.31B
Net Profit Margin
25.48%
TTM Avg
34.77%
3Y Avg
31.87%
5Y Avg
32.80%
Market Cap
$5.30B
Net Profit Margin
-3.80%
TTM Avg
-2.80%
3Y Avg
-38.10%
5Y Avg
-60.79%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.66B | -3602.68% | -3360.04% | -14337.31% | N/A |
| RadNet, Inc. (RDNT)vs › | $5.54B | -0.93% | -0.38% | 0.04% | 0.11% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.76B | 9.59% | -0.75% | 21.75% | -53.79% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | -10.21% | -9.94% | -7.18% | -7.18% |
| Kodiak Sciences Inc. (KOD)vs › | $5.82B | 0.00% | 0.00% | 0.00% | 0.00% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.91B | -89.09% | -187.61% | -9430.16% | -6286.77% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 67.88% | 22.01% | 16.68% | 14.76% |
| Doximity, Inc. (DOCS)vs › | $5.31B | 25.48% | 34.77% | 31.87% | 32.80% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.30B | -3.80% | -2.80% | -38.10% | -60.79% |
| GRAIL Inc. (GRAL)vs › | $6.01B | -236.95% | -945.70% | -3296.24% | -3620.73% |
Operating Margin
-4722.1%
Net Profit Margin
-3602.7%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -6832.84% |
| 2026-03-31 | -5558.82% |
| 2025-12-31 | -1779.03% |
| 2025-09-30 | -2629.53% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | -66253.85% |
| 2024-12-31 | -6973.25% |
| 2024-09-30 | -47453.49% |
| 2024-06-30 | -17028.83% |
| 2024-03-31 | -3200.76% |
| 2023-12-31 | -1611600.00% |
| 2023-09-30 | -130755.56% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -4467.53% |
| 2022-12-31 | 0.00% |
